XML 89 R72.htm IDEA: XBRL DOCUMENT v3.8.0.1
Earnings Per Common Share Attributable to Common Shareholders (Details) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Oct. 01, 2017
Oct. 02, 2016
Oct. 01, 2017
Oct. 02, 2016
EPS Numerator––Basic        
Income from continuing operations [1],[2],[3] $ 2,858 $ 1,355 $ 9,064 $ 6,465
Less: Net income attributable to noncontrolling interests 18 0 32 25
Income from continuing operations attributable to Pfizer Inc. [1] 2,840 1,355 9,032 6,440
Less: Preferred stock dividends––net of tax 0 0 1 1
Income from continuing operations attributable to Pfizer Inc. common shareholders [1] 2,839 1,355 9,032 6,439
Discontinued operations––net of tax [3] 0 0 1 0
Net income attributable to Pfizer Inc. common shareholders [1] 2,839 1,355 9,033 6,439
EPS Numerator––Diluted        
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions [1] 2,840 1,355 9,032 6,440
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions 0 0 1 0
Net income attributable to Pfizer Inc. common shareholders and assumed conversions [1] $ 2,840 $ 1,355 $ 9,034 $ 6,440
EPS Denominator        
Weighted-average number of common shares outstanding––Basic [3] 5,951 6,066 5,972 6,095
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares) [1] 89 84 85 80
Weighted-average number of common shares outstanding––Diluted [1],[2],[3] 6,041 6,150 6,057 6,175
Equity Option [Member]        
EPS Denominator        
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (shares) [1],[4] 47 38 47 60
[1] Amounts for the third quarter and first nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B).
[2] Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies––Adoption of New Accounting Standards.
[3] Amounts may not add due to rounding.
[4] These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.